Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety outcomes of Cecolin HPV16/18 vaccine: observational database study
CTR20231719Phase 4Completed
- Sponsor
- Xiamen University
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, Cervical Cancer (CC), HPV-related anogenital disease (HPV-AGD), sponsored by Xiamen University. Started Jun 2023; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18Cervical Cancer (CC)HPV-related anogenital disease (HPV-AGD)
Beyond the preview
Go deeper on CTR20231719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231719.